Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
Details for the oral presentation are as follows:
|Title:||Dual GLP-1 Agonists in the Treatment Metabolic & Liver Dysfunction in NASH|
Details for the panel discussion are as follows:
|Title:||Is the Cure for NASH Better Treatment of Obesity?|
A copy of Dr. Harris’ presentation and poster will be accessible on the Events section of the Altimmune website.
About the 4th Annual NASH Summit 2020
The digital 4th Annual NASH Summit 2020
ALT-801 is a novel peptide-based dual GLP-1/glucagon receptor agonist that is designed to treat the obesity and metabolic dysfunction that causes NASH. As the most severe form of non-alcoholic fatty liver disease, or NAFLD, NASH involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, resulting ultimately in fibrosis (cirrhosis) or liver cancer. Altimmune believes the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH. As observed in a well-established preclinical model of the disease, ALT-801 was capable of inducing significantly greater weight loss compared to semaglutide, a GLP-1 receptor agonist, along with significantly greater decreases in liver fat, plasma ALT, and other markers of NASH. ALT-801 is currently in Phase 1 development with initial data readouts expected during Q2 2021.
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
|Chief Financial Officer|
Sr. Director, Investor Relations
Source: Altimmune, Inc.